Filed with the SEC on · Summarized by InvestorsBot
AbbVie EVP and Chief Business and Strategy Officer Nicholas Donoghoe sold 32,710 shares of common stock on August 14 at $250.00 per share, for approximately $8,177,500. He owned 74,430 shares after the sale.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeAbbVie Completes $10 Billion Debt Offering to Fund Apogee Acquisition
8-K · August 18, 2026
AbbVie launches $10 billion bond offering to fund Apogee acquisition
8-K · August 5, 2026
AbbVie reports 10.2% revenue growth and agrees to acquire Apogee for $10.9 billion
8-K · July 31, 2026
AbbVie 8-K (Item 9.01) — Supplemental Indenture No.
8-K · March 4, 2026
On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…
8-K · March 4, 2026
AbbVie ($ABBV) filed Form 8‑K (Item 9.01) attaching an Underwriting Agreement dated Feb 24, 2026 among…
8-K · February 26, 2026